2 news items
Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update
ALLO
13 May 24
and obtaining regulatory approval; the limited nature of the Phase 1 data from our clinical trials and the extent to which such data may or may
Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma
ALLO
26 Apr 24
it difficult to predict the time and cost of product candidate development and obtaining regulatory approval; the limited nature of the Phase 1 data
- Prev
- 1
- Next